BIOVENTUS INC - A (BVS) Fundamental Analysis & Valuation

NASDAQ:BVS • US09075A1088

8.6 USD
-0.3 (-3.37%)
At close: Mar 12, 2026
8.6 USD
0 (0%)
After Hours: 3/12/2026, 8:26:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall BVS gets a fundamental rating of 5 out of 10. We evaluated BVS against 184 industry peers in the Health Care Equipment & Supplies industry. While BVS has a great profitability rating, there are quite some concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on BVS.


Dividend Valuation Growth Profitability Health

7

1. BVS Profitability Analysis

1.1 Basic Checks

  • BVS had positive earnings in the past year.
  • In the past year BVS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
  • BVS had a positive operating cash flow in 4 of the past 5 years.
BVS Yearly Net Income VS EBIT VS OCF VS FCFBVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.33%, BVS is in the better half of the industry, outperforming 78.80% of the companies in the same industry.
  • With an excellent Return On Equity value of 12.35%, BVS belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.
  • BVS has a Return On Invested Capital of 8.50%. This is amongst the best in the industry. BVS outperforms 84.24% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BVS is significantly below the industry average of 9.18%.
  • The 3 year average ROIC (3.98%) for BVS is below the current ROIC(8.50%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.33%
ROE 12.35%
ROIC 8.5%
ROA(3y)-6.97%
ROA(5y)-6.18%
ROE(3y)-34.02%
ROE(5y)-29.59%
ROIC(3y)3.98%
ROIC(5y)N/A
BVS Yearly ROA, ROE, ROICBVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.00%, BVS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • BVS's Profit Margin has improved in the last couple of years.
  • The Operating Margin of BVS (9.91%) is better than 77.72% of its industry peers.
  • In the last couple of years the Operating Margin of BVS has grown nicely.
  • With a decent Gross Margin value of 68.33%, BVS is doing good in the industry, outperforming 75.54% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BVS has remained more or less at the same level.
Industry RankSector Rank
OM 9.91%
PM (TTM) 4%
GM 68.33%
OM growth 3YN/A
OM growth 5Y3.04%
PM growth 3YN/A
PM growth 5Y23.91%
GM growth 3Y1.86%
GM growth 5Y-1.23%
BVS Yearly Profit, Operating, Gross MarginsBVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BVS Health Analysis

2.1 Basic Checks

  • BVS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for BVS has been reduced compared to 1 year ago.
  • BVS has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BVS has an improved debt to assets ratio.
BVS Yearly Shares OutstandingBVS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
BVS Yearly Total Debt VS Total AssetsBVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.50, we must say that BVS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.50, BVS is in line with its industry, outperforming 52.72% of the companies in the same industry.
  • The Debt to FCF ratio of BVS is 4.21, which is a neutral value as it means it would take BVS, 4.21 years of fcf income to pay off all of its debts.
  • BVS has a better Debt to FCF ratio (4.21) than 78.80% of its industry peers.
  • BVS has a Debt/Equity ratio of 1.56. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.56, BVS is not doing good in the industry: 79.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF 4.21
Altman-Z 1.5
ROIC/WACC0.82
WACC10.38%
BVS Yearly LT Debt VS Equity VS FCFBVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • BVS has a Current Ratio of 1.70. This is a normal value and indicates that BVS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.70, BVS is not doing good in the industry: 70.11% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.19 indicates that BVS should not have too much problems paying its short term obligations.
  • The Quick ratio of BVS (1.19) is worse than 69.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.19
BVS Yearly Current Assets VS Current LiabilitesBVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BVS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.68% over the past year.
  • Measured over the past years, BVS shows a very strong growth in Earnings Per Share. The EPS has been growing by 32.76% on average per year.
  • BVS shows a decrease in Revenue. In the last year, the revenue decreased by -0.91%.
  • The Revenue has been growing by 12.08% on average over the past years. This is quite good.
EPS 1Y (TTM)44.68%
EPS 3Y61.98%
EPS 5Y32.76%
EPS Q2Q%60%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y3.52%
Revenue growth 5Y12.08%
Sales Q2Q%2.77%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.25% on average over the next years. This is quite good.
  • Based on estimates for the next years, BVS will show a small growth in Revenue. The Revenue will grow by 6.77% on average per year.
EPS Next Y14.86%
EPS Next 2Y14.11%
EPS Next 3YN/A
EPS Next 5Y12.25%
Revenue Next Year6.78%
Revenue Next 2Y6.62%
Revenue Next 3YN/A
Revenue Next 5Y6.77%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BVS Yearly Revenue VS EstimatesBVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 200M 400M 600M
BVS Yearly EPS VS EstimatesBVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

8

4. BVS Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.65, BVS is valued correctly.
  • Based on the Price/Earnings ratio, BVS is valued cheaper than 89.67% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, BVS is valued rather cheaply.
  • BVS is valuated reasonably with a Price/Forward Earnings ratio of 11.01.
  • Based on the Price/Forward Earnings ratio, BVS is valued cheaply inside the industry as 91.85% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 23.82. BVS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.65
Fwd PE 11.01
BVS Price Earnings VS Forward Price EarningsBVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 92.93% of the companies in the same industry are more expensive than BVS, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BVS indicates a rather cheap valuation: BVS is cheaper than 98.37% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.87
EV/EBITDA 9.57
BVS Per share dataBVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • BVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of BVS may justify a higher PE ratio.
  • BVS's earnings are expected to grow with 14.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.85
PEG (5Y)0.39
EPS Next 2Y14.11%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BVS Dividend Analysis

5.1 Amount

  • No dividends for BVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BVS Fundamentals: All Metrics, Ratios and Statistics

BIOVENTUS INC - A

NASDAQ:BVS (3/12/2026, 8:26:16 PM)

After market: 8.6 0 (0%)

8.6

-0.3 (-3.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-05
Earnings (Next)05-04
Inst Owners77.64%
Inst Owner Change2.28%
Ins Owners2.61%
Ins Owner Change0.55%
Market Cap711.74M
Revenue(TTM)568.09M
Net Income(TTM)22.73M
Analysts82.5
Price Target14.79 (71.98%)
Short Float %2.63%
Short Ratio6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.41%
Min EPS beat(2)9.67%
Max EPS beat(2)29.14%
EPS beat(4)3
Avg EPS beat(4)69.33%
Min EPS beat(4)-0.99%
Max EPS beat(4)239.51%
EPS beat(8)7
Avg EPS beat(8)103.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.15%
Min Revenue beat(2)-0.67%
Max Revenue beat(2)0.96%
Revenue beat(4)2
Avg Revenue beat(4)0.08%
Min Revenue beat(4)-0.67%
Max Revenue beat(4)0.96%
Revenue beat(8)6
Avg Revenue beat(8)3.18%
Revenue beat(12)10
Avg Revenue beat(12)3.35%
Revenue beat(16)11
Avg Revenue beat(16)1.45%
PT rev (1m)-3.33%
PT rev (3m)-3.33%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 12.65
Fwd PE 11.01
P/S 1.25
P/FCF 9.87
P/OCF 9.53
P/B 3.87
P/tB N/A
EV/EBITDA 9.57
EPS(TTM)0.68
EY7.91%
EPS(NY)0.78
Fwd EY9.08%
FCF(TTM)0.87
FCFY10.13%
OCF(TTM)0.9
OCFY10.49%
SpS6.86
BVpS2.22
TBVpS-2.32
PEG (NY)0.85
PEG (5Y)0.39
Graham Number5.83
Profitability
Industry RankSector Rank
ROA 3.33%
ROE 12.35%
ROCE 10.76%
ROIC 8.5%
ROICexc 9.42%
ROICexgc 46.29%
OM 9.91%
PM (TTM) 4%
GM 68.33%
FCFM 12.69%
ROA(3y)-6.97%
ROA(5y)-6.18%
ROE(3y)-34.02%
ROE(5y)-29.59%
ROIC(3y)3.98%
ROIC(5y)N/A
ROICexc(3y)4.38%
ROICexc(5y)N/A
ROICexgc(3y)24.58%
ROICexgc(5y)N/A
ROCE(3y)5.03%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.39%
ROICexc growth 3YN/A
ROICexc growth 5Y4.41%
OM growth 3YN/A
OM growth 5Y3.04%
PM growth 3YN/A
PM growth 5Y23.91%
GM growth 3Y1.86%
GM growth 5Y-1.23%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF 4.21
Debt/EBITDA 2.78
Cap/Depr 5.45%
Cap/Sales 0.45%
Interest Coverage 2.08
Cash Conversion 72.29%
Profit Quality 317.22%
Current Ratio 1.7
Quick Ratio 1.19
Altman-Z 1.5
F-Score8
WACC10.38%
ROIC/WACC0.82
Cap/Depr(3y)6.77%
Cap/Depr(5y)11.29%
Cap/Sales(3y)0.69%
Cap/Sales(5y)1.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.68%
EPS 3Y61.98%
EPS 5Y32.76%
EPS Q2Q%60%
EPS Next Y14.86%
EPS Next 2Y14.11%
EPS Next 3YN/A
EPS Next 5Y12.25%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y3.52%
Revenue growth 5Y12.08%
Sales Q2Q%2.77%
Revenue Next Year6.78%
Revenue Next 2Y6.62%
Revenue Next 3YN/A
Revenue Next 5Y6.77%
EBIT growth 1Y128.66%
EBIT growth 3YN/A
EBIT growth 5Y15.49%
EBIT Next Year49.52%
EBIT Next 3YN/A
EBIT Next 5Y17.26%
FCF growth 1Y90.83%
FCF growth 3YN/A
FCF growth 5Y1.27%
OCF growth 1Y92.48%
OCF growth 3YN/A
OCF growth 5Y0.79%

BIOVENTUS INC - A / BVS FAQ

Can you provide the ChartMill fundamental rating for BIOVENTUS INC - A?

ChartMill assigns a fundamental rating of 5 / 10 to BVS.


What is the valuation status for BVS stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOVENTUS INC - A (BVS). This can be considered as Undervalued.


Can you provide the profitability details for BIOVENTUS INC - A?

BIOVENTUS INC - A (BVS) has a profitability rating of 7 / 10.


What is the valuation of BIOVENTUS INC - A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOVENTUS INC - A (BVS) is 12.65 and the Price/Book (PB) ratio is 3.87.


What is the financial health of BIOVENTUS INC - A (BVS) stock?

The financial health rating of BIOVENTUS INC - A (BVS) is 3 / 10.